Orforglipron
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight
Eli Lilly · Phase 1 · Completed · Enrollment 533
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Part A: LY3502970 QD Oral Administration (Cohort 1A, Sequence 1) | n/r | n/r | n/r | n/r |
| Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 2) | n/r | n/r | n/r | n/r |
| Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 3) | n/r | n/r | n/r | n/r |
| Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 4) | n/r | n/r | n/r | n/r |
| Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 1) | n/r | n/r | n/r | n/r |
| Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 2) | n/r | n/r | n/r | n/r |
| Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 3) | n/r | n/r | n/r | n/r |
| Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 4) | n/r | n/r | n/r | n/r |
| Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 1) | n/r | n/r | n/r | n/r |
| Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 2) | n/r | n/r | n/r | n/r |
| Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 3) | n/r | n/r | n/r | n/r |
| Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 1) | n/r | n/r | n/r | n/r |
| Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 2) | n/r | n/r | n/r | n/r |
| Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 3) | n/r | n/r | n/r | n/r |
Not shown
- Part A: LY3502970 QD Oral Administration (Cohort 1A, Sequence 1): endpoint not reported
- Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 2): endpoint not reported
- Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 3): endpoint not reported
- Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 4): endpoint not reported
- Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 1): endpoint not reported
- Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 2): endpoint not reported
- Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 3): endpoint not reported
- Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 4): endpoint not reported
- Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 1): endpoint not reported
- Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 2): endpoint not reported
- Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 3): endpoint not reported
- Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 1): endpoint not reported
- Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 2): endpoint not reported
- Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 3): endpoint not reported